Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr David Grieve
Department:Centre for Experimental Medicine
Organisation:Queen's University Belfast
- genetics, genomics and molecular biology
- cell and developmental biology/regenerative medicine
- physiology and non-communicable disease
Postgrad Medical Specialties
- Sports and Exercise Medicine
- Vascular Medicine
My research programme is mainly focussed on investigating mechanisms underlying cardiovascular remodelling and dysfunction, with a particular interest in the role of oxidative stress, novel peptide hormones, endothelial progenitor cells, and the influence of diabetes. My group employs a wide range of laboratory techniques, from in vivo physiology to molecular biology and tissue culture, to investigate mechanisms underlying the adaptive but ultimately detrimental changes that occur in various cardiovascular disease states and how these may be modulated for potential therapeutic benefit.
Ongoing translational research projects include:
• Endothelial Nox2 NADPH oxidase as a key driver of adverse cardiac remodelling associated with diabetes
• Influence of Nox4 NADPH oxidase on endothelial progenitor cell function and their ability to promote angiogenesis in tissue ischaemia
• Does Nox4 NADPH oxidase play a key role in direct reprogramming of fibroblasts into endothelial cells and underlie their ability to promote angiogenesis?
• Selective targeting of glucagon-like peptide-1 as a novel approach to prevent adverse cardiovascular remodelling associated with diabetes
• Identification of prognostic circulating microRNA-based markers of diabetic patient outcome after aortic valve replacement surgery
See below abstract of an example research project for a clinical PhD in our group. Projects may be tailored to specific areas of interest within cardiovascular medicine. We are happy to develop novel projects together with prospective candidates aimed at addressing important clinical problems by utilising our state-of-the-art research methods and wide-ranging expertise towards ultimate benefit for patients.
Identification of prognostic circulating microRNA-based markers of diabetic patient outcome after aortic valve replacement surgery:
Further to the global diabetes epidemic, increasing patient numbers require cardiac surgery, with this population displaying worse post-surgical outcomes, including advanced diastolic dysfunction, which is an independent predictor of mortality and may underlie enhanced susceptibility to cardiac stress (e.g. ischaemia) in diabetes. Indeed, the diabetic heart is characterised by inflammation and aberrant extracellular matrix remodelling, which may underlie cardiac stiffness, subclinical diastolic dysfunction and accelerated heart failure progression. However, identifying those diabetic patients prone to poor outcomes is difficult. In this regard, microRNAs (miRNAs), which regulate multiple mRNA targets and are secreted/expressed within the cardiovascular system, represent potential biomarkers for extracellular matrix remodelling in diabetes. We therefore aim to (1) characterise specific miRNA alterations in cardiac fibroblasts/blood from diabetic patients and correlate with post-surgical outcomes; (2) profile inflammatory cells in diabetic patients and study their interaction with cardiac fibroblasts in vitro. This will be achieved by employing state-of the-art sequencing technology and other established laboratory techniques. We are confident that this work will identify novel circulating markers and/or signalling pathways that may be associated with poor surgical outcome after cardiac surgery which can be exploited for effective clinical stratification.